Article

Proliferative myositis: expanding the differential diagnosis of a soft tissue mass in infancy

Division of Pediatric Orthopaedics, Cincinnati Children's Hospital Medical Center, 3333 Burnet Avenue, Cincinnati, OH 45229, USA.
Skeletal Radiology (Impact Factor: 1.74). 09/2011; 40(12):1623-7. DOI: 10.1007/s00256-011-1274-4
Source: PubMed

ABSTRACT Proliferative myositis, a pseudosarcomatous lesion of skeletal muscle, is quite rare in the pediatric population. While benign, it is not always recognized as such, and may be treated with an extensive resection that can result in permanent disfigurement. We report a case of an infant with the diagnosis of proliferative myositis, who to our knowledge is the youngest patient to be evaluated with magnetic resonance imaging (MRI). Although the MRI findings are non-specific, we highlight the importance of considering proliferative myositis in the differential diagnosis of a soft tissue mass, which ultimately might prevent an overly aggressive resection in a child.

0 Followers
 · 
102 Views
  • [Show abstract] [Hide abstract]
    ABSTRACT: Objective Leukemia is a group of malignant diseases involving peripheral blood and bone marrow. Extramedullary tumor manifestation in leukemia can also occur. They more often involve lymph nodes, skin, and bones. Intramuscular leukemic relapse (ILR) is very unusual. The aim of this analysis was to summarize the reported data regarding clinical signs and radiological features of ILR. Material and methods The PubMed database was searched for publications related to ILR. After an analysis of all identified articles, 20 publications matched the inclusion criteria. The authors of the 20 publications were contacted and provided imaging of their cases for review. The following were recorded: age, gender, primary diagnosis, clinical signs, pattern, localization and size of the intramuscular leukemic relapse. Images of 16 patients were provided [8 computer tomographic (CT) images and 15 magnetic resonance images, MRI]. Furthermore, one patient with ILR was identified in our institutional database. Therefore, images of 17 patients were available for further analysis. Results Overall, 32 cases with ILR were included in the analysis. In most cases acute myeloid leukemia was diagnosed. Most ILRs were localized in the extremities (44 %) and in the extraocular muscles (44 %). Clinically, ILR manifested as local pain, swelling and muscle weakness. Radiologically, ILR presented most frequently with diffuse muscle infiltration. On postcontrast CT/MRI, most lesions demonstrated homogeneous enhancement. ILRs were hypo-/isointense on T1w and hyperintense on T2w images. Conclusion ILR manifests commonly as focal pain, swelling and muscle weakness. ILR predominantly involved the extraocular musculature and the extremities. Radiologically, diffuse muscle infiltration was the most common imaging finding.
    Skeletal Radiology 09/2014; 44(4). DOI:10.1007/s00256-014-2009-0 · 1.74 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: M u s c u l o s ke l e t a l I m ag i ng • R ev i ew anaerobic organisms such as Clostridium species, Proteus species, Escherichia coli, Bacteroides species, Enterobacteriaceae spe-cies, and others [1–8]. The entity is a medi-cal emergency with reported mortality rates as high as 70–80%, with common causes of death including sepsis or respiratory, renal, or multisystem organ failure [2, 6–8]. Necrotizing fasciitis is divided into types I and II by the Society of Infectious Dis-ease according to bacteriology profile [6–9]. Type I involves a mixed infection with aero-bic and anaerobic bacteria and is most com-monly seen in patients with diabetes melli-tus, peripheral vascular disease, alcoholism, malignancy (especially leukemia and lym-phoma), immunocompromise, and postsurgi-cal status (especially transplantations) [1–6]. Fournier gangrene refers to necrotizing fasci-itis of the perineum and is usually of the type I variety [6, 7, 10]. Type II necrotizing fasci-itis is caused by group A Streptococcus (GAS, S. pyogenes) or Staphylococcus aureus and re-sults in gangrenous myofasciitis with the po-tential complication of toxic shock syndrome (primarily through release of exotoxins A, B, and C) [6, 7, 9]. M-protein is a key molecu-lar virulent factor in GAS organisms and has antiphagocytic properties which allow the in-N ecrotizing fasciitis and its differ-ential diagnoses are often en-countered in the emergency de-partment and inpatient settings. Although a clinical diagnosis, cross-sectional imaging is nonetheless frequently performed for evaluation of disease extent and complica-tions. Therefore, radiologists should be famil-iar with the entity and its mimics. This article will describe the clinical features, imaging findings, pathophysiology, treatment options, and prognosis of necrotizing fasciitis and oth-er soft-tissue processes (nonnecrotizing fasci-itis, myositis, myonecrosis, and cellulitis) re-sulting from infection, inflammation, injury, or malignancy. The representative imaging examples are predominately from extremities, with the exception of Fournier gangrene and dermatomyositis. Necrotizing Fasciitis Necrotizing fasciitis is a rapidly progres-sive often fatal soft-tissue infection most commonly resulting from polymicrobial in-fection. The process initially begins in the superficial fascial planes and progresses into the deep fascial layers causing necrosis by microvascular occlusion. Causative in-fectious agents tend to be both aerobic and
    American Journal of Roentgenology 01/2015; 204(1):128-139. DOI:10.2214/AJR.14.12676 · 2.74 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: This review updates recent trends in the classification of the juvenile idiopathic inflammatory myopathies (JIIM) and the emerging standard of treatment of the most common form of JIIM, juvenile dermatomyositis. The JIIM are rare, heterogeneous autoimmune diseases that share chronic muscle inflammation and weakness. A growing spectrum of clinicopathologic groups and serologic phenotypes defined by the presence of myositis autoantibodies are now recognized, each with differing demographics, clinical manifestations, laboratory findings, and prognoses. Although daily oral corticosteroids remain the backbone of treatment, disease-modifying anti-rheumatic drugs are almost always used adjunctively and biologic therapies may benefit patients with recalcitrant disease.
    Rheumatic diseases clinics of North America 11/2013; 39(4):877-904. DOI:10.1016/j.rdc.2013.06.001 · 1.74 Impact Factor